Background: Acute myeloid leukemia (AML) is a malignant clonal disorder characterized by mutations affecting myeloid differentiation, gene expression, and epigenetic profiles. Although treatment strategy depends on a genetic profile-based risk, the accuracy of this stratification system is highly variable. Changes in gene expression profiles of signaling pathways involved in hematopoietic development, such as Wnt/B-catenin, may contribute to the transformation, development, and maintenance of leukemic cells, and could be related to the clinical outcome. Methods: qRT-PCR assays were designed to quantify mRNA levels of c-Myc, and B-catenin in blood samples from nine newly diagnosed AML patients before and after treatment. 18S ribosomal RNA was used to normalize gene expression. Statistical analysis was conducted in R statistical software. Relative expression rates (rERs) were implemented to quantify relative changes in gene expression levels after induction. Results: c-Myc and B-catenin expression decreased after induction treatment. Additionally, the rERs of both genes were linearly correlated (r = 0.937, p = 0.0002), and patients who has persistence of the disease after treatment have a higher rER -in both c-Myc and B-catenin-, compared to those who achieve complete remission (c-Myc: p = 0.0066; B-catenin: p = 0.04). However, c-Myc and B-catenin rERs were greatly variable in patients who partially responded to induction. Conclusions: c-Myc and B-catenin are molecules from Wnt signaling pathway, related to activation of the molecular pathway. Patients who have a decrease in the expression of this genes are more likely to achieve complete remission than those who don't change the expression of this molecules. Further analyses are needed to determine the precise role of Wnt/B-catenin in AML therapy response. Legal entity responsible for the study: Instituto Tecnológico Metropolitano. Funding: Colciencias, grant 669-2014. Disclosure: All authors have declared no conflicts of interest.